Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. In approximately 80% of patients, auto-antibodies to the muscle nicotinic acetylcholine receptor ...

These data indicate the differentiated mechanism of TSLP receptor targeting with verekitug may drive the greater potency observed with this approach as compared with targeting the TSLP ligand.

Who Ultomiris is prescribed for Ultomiris is prescribed to treat generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive.

Certain antibodies block the regular acetylcholine binding process, the researchers found, while others activate the immune system's complement pathway, leading to receptor destruction.

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer The following represents ...

Laekna team is developing more drug candidates to maximize the value of targeting ActRII receptors. LAE103 is an ActRIIB-selective antibody and LAE123 is a dual inhibitor for ActRIIA/IIB.

More than 60% of complement inhibitor–naive patients with acetylcholine receptor–positive generalized myasthenia gravis (MG) in diverse clinical populations had a clinically meaningful ...

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated ...

Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social ...